Impact of antiretroviral therapy on depression and sleep disorders in HIV patients

Detalhes bibliográficos
Autor(a) principal: Medeiros, Melissa Soares
Data de Publicação: 2021
Outros Autores: Granjeiro, Liliane Nogueira, Alves, Yandra Mirelle Nogueira, Castro Junior, Jose Edvar di, Lima, Luan Victor Almeida
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/19989
Resumo: Depression and sleep disorders are frequent in patients with HIV. The aim of this article is to detect sleep disorders and depression related to antiretroviral therapy in the adult population with HIV/AIDS. The following scales were applied: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adapted to Brazil (ESS-Br), and the Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. In the sleep assessment (PSQI), use of Dolutegravir (DTG) showed 58.8% poor sleep quality, Efavirenz (EFZ) was 38% indicative of poor sleep and 28.5% of sleep disorder, and Atazanavir-ritonavir (ATV-r) with poor quality sleep was found in 40%. The detection of any type of sleep disorder did not differ statistically between the use of EFZ or DTG (p = 0.79). Regarding the assessment of ESS-Br sleepiness, we detected 4.7%, 17.2% and 20% important alterations in patients using EFZ, DTG and ATV, respectively. The analysis obtained for depression (PHQ-9) was moderately severe (EFZ = 10%, DTG = 20.3%, ATV = 0%) and severe (EFZ = 15%, DTG = 6.2%, ATV = 0%). This study showed that HIV-positive individuals suffer from sleep disturbances independent of the ART regimen, but with greater impact with Efavirenz. Daytime sleepiness was present in one in every 5 individuals using ART. And the greater severity of depression was found to be important for the groups using Efavirenz and Dolutegravir.
id UNIFEI_18efa25272ded3b20d1c2241b82fe73f
oai_identifier_str oai:ojs.pkp.sfu.ca:article/19989
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Impact of antiretroviral therapy on depression and sleep disorders in HIV patientsImpacto de la terapia antirretroviral en la depresión y los trastornos del sueño en pacientes con VIHImpacto da terapia antirretroviral na depressão e transtorno do sono em pacientes portadores de HIV Distúrbio do sonoHIVDepressãoTerapia antirretroviralEfavirenzDolutegravirAtazanavir.Sleep disordersHIVDepressionAntiretroviral therapyEfavirenzDolutegravirAtazanavir.Alteración del sueñoVIHDepresiónTerapia antirretroviralEfavirenzDolutegravirAtazanavir.Depression and sleep disorders are frequent in patients with HIV. The aim of this article is to detect sleep disorders and depression related to antiretroviral therapy in the adult population with HIV/AIDS. The following scales were applied: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adapted to Brazil (ESS-Br), and the Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. In the sleep assessment (PSQI), use of Dolutegravir (DTG) showed 58.8% poor sleep quality, Efavirenz (EFZ) was 38% indicative of poor sleep and 28.5% of sleep disorder, and Atazanavir-ritonavir (ATV-r) with poor quality sleep was found in 40%. The detection of any type of sleep disorder did not differ statistically between the use of EFZ or DTG (p = 0.79). Regarding the assessment of ESS-Br sleepiness, we detected 4.7%, 17.2% and 20% important alterations in patients using EFZ, DTG and ATV, respectively. The analysis obtained for depression (PHQ-9) was moderately severe (EFZ = 10%, DTG = 20.3%, ATV = 0%) and severe (EFZ = 15%, DTG = 6.2%, ATV = 0%). This study showed that HIV-positive individuals suffer from sleep disturbances independent of the ART regimen, but with greater impact with Efavirenz. Daytime sleepiness was present in one in every 5 individuals using ART. And the greater severity of depression was found to be important for the groups using Efavirenz and Dolutegravir.La depresión y los trastornos del sueño son frecuentes en pacientes con VIH. El objetivo de este artículo es detectar los trastornos del sueño y la depresión relacionados con la terapia antirretroviral en la población adulta con VIH / SIDA. Se aplicaron las siguientes escalas: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adaptada a Brasil (ESS-Br) y Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. En la evaluación del sueño (PSQI), el uso de Dolutegravir (DTG) mostró un 58.8% de mala calidad del sueño, el Efavirenz (EFZ) fue un 38% indicativo de sueño deficiente y un 28.5% de trastorno del sueño, y el Atazanavir-ritonavir (ATV-r) con sueño de mala calidad se encontró en el 40%. La detección de cualquier tipo de trastorno del sueño no difirió estadísticamente entre el uso de EFZ o DTG (p = 0,79). En cuanto a la valoración de la somnolencia ESS-Br, detectamos alteraciones importantes del 4,7%, 17,2% y 20% en pacientes que utilizan EFZ, DTG y ATV, respectivamente. El análisis obtenido para la depresión (PHQ-9) fue: moderadamente grave (EFZ = 10%, DTG = 20,3%, ATV = 0%) y grave (EFZ = 15%, DTG = 6,2%, ATV = 0%). Este estudio mostró que las personas VIH positivas sufren alteraciones del sueño independientes del régimen de TAR, pero con mayor impacto con Efavirenz. La somnolencia diurna estuvo presente en uno de cada 5 individuos que usaban TAR. Y se descubrió que la mayor gravedad de la depresión era importante para los grupos que usaban efavirenz y dolutegravir.Depressão e alteração do sono são frequentes em pacientes portadores de HIV. O objetivo deste artigo é detectar alterações no sono e depressão relacionados a terapia antirretroviral na população adulta com HIV/aids. Aplicadas as escalas: Patient Health Questionnaire-9 (PHQ-9), Escala de Sonolência Epworth, adaptada ao Brasil (ESS-Br), e do Questionário Índice de Qualidade do Sono de Pittsburgh (PSQI). CEP: 3.319.628. Na avaliação do sono (PSQI), uso de Dolutegravir (DTG) apresentou 58,8% sono de qualidade ruim, Efavirenz (EFZ) foi 38% indicativo de sono ruim e 28,5% de distúrbio do sono, e Atazanavir/ritonavir (ATV-r) com sono de qualidade ruim encontrado em 40%. A detecção de qualquer tipo de alteração de sono não diferiu estatisticamente entre uso de EFZ ou DTG (p = 0,79). Com relação à avaliação da sonolência ESS-Br, detectamos 4,7%, 17,2% e 20% alteração importante dos pacientes em uso de EFZ, DTG e ATV, respectivamente. A análise obtida quanto a depressão (PHQ-9) foi: moderadamente grave (EFZ = 10%, DTG = 20,3%, ATV = 0%) e grave (EFZ = 15%, DTG = 6,2%, ATV = 0 %). Este estudo mostrou que indivíduos HIV positivos sofrem de distúrbios do sono independentes do regime de TARV, mas com maior impacto com o Efavirenz.  A sonolência diurna estava presente em um de cada 5 indivíduos em uso de TARV. E a maior gravidade da depressão foi achado importante para os grupos em uso de Efavirenz e Dolutegravir.Research, Society and Development2021-09-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1998910.33448/rsd-v10i12.19989Research, Society and Development; Vol. 10 No. 12; e25101219989Research, Society and Development; Vol. 10 Núm. 12; e25101219989Research, Society and Development; v. 10 n. 12; e251012199892525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/19989/17924Copyright (c) 2021 Melissa Soares Medeiros; Liliane Nogueira Granjeiro; Yandra Mirelle Nogueira Alves; Jose Edvar di Castro Junior; Luan Victor Almeida Limahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMedeiros, Melissa Soares Granjeiro, Liliane Nogueira Alves, Yandra Mirelle Nogueira Castro Junior, Jose Edvar di Lima, Luan Victor Almeida 2021-11-14T20:26:51Zoai:ojs.pkp.sfu.ca:article/19989Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:45.576532Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
Impacto de la terapia antirretroviral en la depresión y los trastornos del sueño en pacientes con VIH
Impacto da terapia antirretroviral na depressão e transtorno do sono em pacientes portadores de HIV
title Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
spellingShingle Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
Medeiros, Melissa Soares
Distúrbio do sono
HIV
Depressão
Terapia antirretroviral
Efavirenz
Dolutegravir
Atazanavir.
Sleep disorders
HIV
Depression
Antiretroviral therapy
Efavirenz
Dolutegravir
Atazanavir.
Alteración del sueño
VIH
Depresión
Terapia antirretroviral
Efavirenz
Dolutegravir
Atazanavir.
title_short Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
title_full Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
title_fullStr Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
title_full_unstemmed Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
title_sort Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
author Medeiros, Melissa Soares
author_facet Medeiros, Melissa Soares
Granjeiro, Liliane Nogueira
Alves, Yandra Mirelle Nogueira
Castro Junior, Jose Edvar di
Lima, Luan Victor Almeida
author_role author
author2 Granjeiro, Liliane Nogueira
Alves, Yandra Mirelle Nogueira
Castro Junior, Jose Edvar di
Lima, Luan Victor Almeida
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Medeiros, Melissa Soares
Granjeiro, Liliane Nogueira
Alves, Yandra Mirelle Nogueira
Castro Junior, Jose Edvar di
Lima, Luan Victor Almeida
dc.subject.por.fl_str_mv Distúrbio do sono
HIV
Depressão
Terapia antirretroviral
Efavirenz
Dolutegravir
Atazanavir.
Sleep disorders
HIV
Depression
Antiretroviral therapy
Efavirenz
Dolutegravir
Atazanavir.
Alteración del sueño
VIH
Depresión
Terapia antirretroviral
Efavirenz
Dolutegravir
Atazanavir.
topic Distúrbio do sono
HIV
Depressão
Terapia antirretroviral
Efavirenz
Dolutegravir
Atazanavir.
Sleep disorders
HIV
Depression
Antiretroviral therapy
Efavirenz
Dolutegravir
Atazanavir.
Alteración del sueño
VIH
Depresión
Terapia antirretroviral
Efavirenz
Dolutegravir
Atazanavir.
description Depression and sleep disorders are frequent in patients with HIV. The aim of this article is to detect sleep disorders and depression related to antiretroviral therapy in the adult population with HIV/AIDS. The following scales were applied: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adapted to Brazil (ESS-Br), and the Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. In the sleep assessment (PSQI), use of Dolutegravir (DTG) showed 58.8% poor sleep quality, Efavirenz (EFZ) was 38% indicative of poor sleep and 28.5% of sleep disorder, and Atazanavir-ritonavir (ATV-r) with poor quality sleep was found in 40%. The detection of any type of sleep disorder did not differ statistically between the use of EFZ or DTG (p = 0.79). Regarding the assessment of ESS-Br sleepiness, we detected 4.7%, 17.2% and 20% important alterations in patients using EFZ, DTG and ATV, respectively. The analysis obtained for depression (PHQ-9) was moderately severe (EFZ = 10%, DTG = 20.3%, ATV = 0%) and severe (EFZ = 15%, DTG = 6.2%, ATV = 0%). This study showed that HIV-positive individuals suffer from sleep disturbances independent of the ART regimen, but with greater impact with Efavirenz. Daytime sleepiness was present in one in every 5 individuals using ART. And the greater severity of depression was found to be important for the groups using Efavirenz and Dolutegravir.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-12
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/19989
10.33448/rsd-v10i12.19989
url https://rsdjournal.org/index.php/rsd/article/view/19989
identifier_str_mv 10.33448/rsd-v10i12.19989
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/19989/17924
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 12; e25101219989
Research, Society and Development; Vol. 10 Núm. 12; e25101219989
Research, Society and Development; v. 10 n. 12; e25101219989
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052788942831616